When orals attack: how to ensure product access

William Renzo
William Renzo
William Renzo
SVP, dir. of client services, Ogilvy Healthworld Payer Marketing

Therapeutic categories long dominated by IV-infused therapies face oral-product competition. Gilenya's launch into the IV-infused/self-injection dominated multiple sclerosis market is an example. In this scenario, manufacturers of the oral newcomers face some complexities:

• Will adherence rates be on par with IV-infused/self-injectable competitors?

• Is specialty or retail pharmacy the most appropriate distribution channel?

• How should the oral product be priced to effectively compete with injected therapies?

• Will co-pays or coinsurance be the mechanism most plans use to share costs with patients?

• What patient support services will be required?

• What office manager, nurse, and physician education specific to reimbursement and patient services will be necessary?

When oral-dominated therapeutic categories face IV-infused competition, manufacturers of the new infused therapies face different issues:

• Where will the IV-infused product most likely be administered—physician's office, standalone infusion center, hospital? How will these dynamics impact targeting and promotion?

• Do targeted MDs possess the capabilities to administer IV-infused products in the office? If not, what level of education is needed to ensure physicians understand the dynamics surrounding the product's use?

• What benefits will the new product possess over the oral agents that should be considered when establishing price?

• How will health plans manage the IV-infused therapy? Which stakeholders and processes are needed for advocacy, and what must be understood to ensure optimal reimbursement?

• What Medicare Carrier and Contractor Advisory Committee processes are important to understand to streamline reimbursement?

Many areas of the commercialization strategy and marketing mix are impacted, including distribution, contracts and pricing, health economics and outcomes research, HCP and consumer promotion, training, and site-of-care marketing. With the evolution of science and healthcare reform, remaining a step ahead of these paradigm shifts may prove the difference between leaders and followers.

You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


Investment in healthcare IT stands at an all-time high. The government has spent billions to promote EHR adoption. Yet the physician wish list is a mile long, while hospitals and patients are not where they need to be. To peel back the layers of what we've all been waiting for in the Great Data Capture of the 21st Century, and to review the changes enabling the healthcare data ecosystem to coexist, MM&M presents this e-Book. Click here.


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.